In a decisive move to globalize its leadership and ambitions, South Korean aesthetics major Hugel Inc. has appointed Carrie Strom, a seasoned US pharmaceutical executive, as its President and Global Chief Executive Officer, effective immediately.
This marks the creation of a newly formed global CEO position at Hugel—one that signals a shift from domestic dominance to full-fledged international expansion. Strom, best known for her leadership of Allergan Aesthetics under AbbVie, will oversee Hugel’s growing portfolio and its executive leadership across all markets, including Korea.
Her appointment is expected to be formalized with a board seat pending shareholder approval at an upcoming general meeting.
From Botox to Botulax: A Global Operator Takes the Helm
If there’s a leader tailor-made for this role, it’s Strom. Over a 25-year career, she’s scaled some of the most recognizable names in aesthetics. As Global President of Allergan Aesthetics, she managed a $5 billion portfolio across 50+ countries, including heavyweights like Botox Cosmetic and Juvedérm. Before that, she led Allergan’s U.S. medical aesthetics business and spent over a decade in commercial leadership at Pfizer.
“I am honored to join Hugel as CEO,” said Strom in a statement. “My priority is to build on Hugel’s leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world.”
Hugel’s Next Chapter: Playing Offense on the Global Stage
Founded in 2001, Hugel has quietly grown into a market leader in botulinum toxin and dermal fillers—two high-margin segments at the heart of the $75B+ global aesthetics market. Best known in Korea for Botulax®, the company sells the product internationally under the brand Letybo®, now registered in 69 countries. Its hyaluronic acid fillers are marketed in 53 nations.
But beyond regulatory reach, Hugel’s most telling advantage may be its rare trifecta: **it holds approvals in the world’s three largest medical aesthetics markets—**the United States, China, and the European Union. No other South Korean aesthetics player can claim the same.
The company now operates nine subsidiaries across North America, Asia-Pacific, and Australia, and is seen as a rising challenger to Western incumbents like Revance and Ipsen.
The Global CEO Mandate: Integration, Brand, and Scale
With Strom’s appointment, Hugel is not just hiring for experience—it’s hiring for transformation. The newly created global CEO role consolidates leadership across functions and markets, positioning Hugel to operate more cohesively as a multinational brand. Daniel Chang, recently named head of Hugel Korea, will now report directly to Strom.
Hugel’s board is framing the move as both symbolic and strategic.
“Carrie Strom is a proven enterprise leader who we are confident will lead Hugel to the next level,” said Suk Cha, Chairman of the Board. “We look forward to accelerating our expansion in the Americas and other key global markets under her leadership.”
Editorial View: A Strategic Crossroads for Korean Aesthetics
Carrie Strom’s arrival comes at a pivotal time—not just for Hugel, but for the broader Korean aesthetics sector. While Korea has long been a hub of innovation and procedural excellence in beauty and dermatology, few companies have successfully translated domestic leadership into global brand authority.
With global brands like Botox dominating mindshare, South Korean players have historically struggled to punch above their weight in consumer perception and provider loyalty—especially in North America and Europe.
Hugel is betting that global leadership, combined with Korean innovation and manufacturing prowess, can change that. Strom, with her operational fluency in the West and understanding of the product playbook, is uniquely equipped to bridge that gap.
But globalizing an aesthetics company is not just a regulatory or distribution challenge—it’s a branding war. Hugel will need to articulate a clearer identity, refine its positioning, and command clinical trust in markets where Allergan and AbbVie have had a head start for decades.
Strom’s playbook from Allergan—where product ecosystems, provider training, and emotional brand resonance were key—may offer Hugel a blueprint not just to scale, but to lead.
—
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
